Market Overview

Transcept Pharmaceuticals Issues Statement on Dismissal of Derivative Lawsuit

Transcept Pharmaceuticals (Nasdaq: TSPT) today announced the dismissal of the derivative lawsuit by the Court of Chancery of the State of Delaware. The derivative lawsuit was filed on October 24, 2013, by a shareholder, Retrophin Inc., against the Transcept Board of Directors, purporting to assert claims on behalf of Transcept, alleging that our Board of Directors approved and paid excessive compensation to our directors.

See full press release

Posted-In: News Guidance Legal Management Global

 

Most Popular

Related Articles (TSPT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free